University of Illinois at Chicago
Chicago, IL
Filters
Save & Share
Clear Filters
Diagnosis
Treatment History
BCMA Therapy
This stands for B Cell Maturation Antigen (BCMA) and includes treatments such as ide-cel, cilta-cel or belantamab mafodotin.
Accepting patients
MonumenTAL-3
Phase 3 Clinical Trial Comparing the Efficacy of an Investigational Medication Combined with Daratumumab or Daratumumab and Pomalidomide Versus Daratumumab, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.
Learn more- Bispecific Antibody
- GPRC5D
- Randomization
- Phase 3
Not yet accepting
Personalized Autologous Transplant
Personalized Autologous Transplant for Multiple Myeloma
Learn more- Autologous Stem Cell Transplant
- Vaccine
- Phase 1
Accepting patients
DRAMMATIC
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)
Learn more- Monoclonal Antibody
- CD38
- Maintenance
- Phase 3
Accepting patients
HEME-20
Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD) (HEME-20)
Learn more- Maintenance
- Pilot Trial
Accepting patients
HEME-18
Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma
Learn more- Monoclonal Antibody
- CD38
- Maintenance
- Minimal Residual Disease (MRD)
- Phase 2
Accepting patients
CERVINO
A Phase 3, Multicenter, Randomized, Open Label Study of ABBV-383 Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)
Learn more- Bispecific Antibody
- BCMA
- CD3
- Randomization
- Phase 3
1 hidden based on your filters. Show All